ScienceIO
AcquiredFounded 2019 · 8 employees on LinkedIn · 25 known investors
ScienceIO offers an AI platform for interpreting healthcare data, including a product that converts unstructured medical text into structured data via an API and maps it to millions of medical concepts. It serves organizations working with medical and healthcare data.
Also known as Science IO
Founders & leadership
ScienceIO was founded in 2019 by Will Manidis and Gaurav Kaushik.
Investors · 25
Also in the syndicate · 12
Funding
SEC filings, press & company announcements- Undisclosed amountSeedOct 2021 · 2 sourcesSource ↗
Source: company announcements and press reports — follow each round's link for the claim.
Company profile
researched Aug 2026ScienceIO is a healthcare data science company that applies natural language processing and machine learning to unstructured medical text, converting it into structured, computable data that healthcare organizations can search, analyze and build on. Its platform recognizes and links biomedical terms — conditions, procedures, therapies, drugs, devices, genes and biomarkers — to a repository of over 9 million medical concepts, using contextual cues so that a single API call can extract and map the medical content of a document.
The company packages this capability into three products: Identify, which locates Protected Health Information so records can be integrated and patient profiles built; Redact, which removes Protected Health Information from documents to protect patient privacy; and Structure, which finds and maps medical terms to the concept repository in one API call, accepting up to 10,000 characters per call and returning real-time results. Stated use cases include patient cohort selection from unstructured clinical documentation, digital health analysis of patient messages for status and risk, commercial landscaping across pharmaceutical and biotech developments, payor claims adjustment workflows, diagnostics and biomarker identification including genomic information, and revenue cycle management tasks such as flagging coding errors and missed diagnoses. Broader model capabilities described at the time of its acquisition include patient anonymization, record linkage, information extraction, summarization and predictive analytics.
ScienceIO states that it does not track individuals; it makes data more searchable and produces analytics that can be converted into insights. The company describes its mission as digitizing and organizing healthcare data to make it useful and accessible to software engineers.
Founding story
Co-founder Gaurav Kaushik developed the premise while working in 2018 with a Boston-based cancer research company and Flatiron Health on relationships between cancer patients, tumor mutations and outcomes; his team's analysis suggested patients with triple-negative breast cancer respond well to immunotherapies, which highlighted the value of connecting unorganized patient data with treatment plans. He co-founded ScienceIO with CEO Will Manidis, a former Thiel Fellow and managing partner of Dorm Room Fund. Kaushik previously led real world data products at Foundation Medicine.
Business model
ScienceIO sells access to its healthcare AI platform to organizations that hold medical data, delivering functionality through APIs and developer documentation that customers embed in their own workflows and applications. At launch it was running pilot programs with several unnamed customers and opened an API early access program for developers, with general availability timing to be determined by pilot results.
Sources describe API-delivered products (Identify, Redact, Structure) sold to healthcare organizations; specific pricing terms are not stated.
Traction
The company reported pilot programs with several undisclosed customers at launch without naming them. It was selected for Mayo Clinic Platform_Accelerate in 2022, and a Mayo Clinic Platform executive is quoted describing its tools identifying at-risk patients and streamlining care. Veradigm, which had an existing partnership with ScienceIO, agreed to acquire the company for $140 million and planned to apply its platform to a data set covering 400,000 providers and more than 200 million patients.
Latest developments
In February 2024 Veradigm, the health IT company formerly known as Allscripts, agreed to acquire ScienceIO for $140 million in cash on hand, with approximately $44 million of the purchase price deferred and payable in installments on the first three anniversaries of closing. Veradigm said it would fully integrate the platform to build proprietary large language models on its own data set and to accelerate features across its provider, payer and life sciences segments. CEO Will Manidis said joining Veradigm aligned with the company's mission to serve patients and healthcare professionals with responsible AI.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
ScienceIO operated in the crowded market of companies attempting to structure healthcare data, positioning its differentiator as a data-first approach and a proprietary training data set it claims is the most representative available. Its acquirer characterized the platform as adding market-leading AI capabilities and an AI center of excellence across provider, payer and life sciences segments.
Company leadership frames the differentiator as the underlying data asset — several years of building a broad, representative healthcare data set intended to capture the totality of a patient rather than reducing them to biorisks — combined with breadth of coverage across more than 9 million medical concepts and simplicity of integration through a single API call.
Technology
The platform combines natural language processing with machine learning models trained on a proprietary healthcare data set the company spent roughly two to three years assembling before emerging from stealth. It uses contextual cues to identify biomedical terms and link them to larger concepts, covering more than 9 million medical concepts including conditions, drugs, devices and genes, and returns results in real time through a single API call handling up to 10,000 characters. At the time of its acquisition the company was described as specializing in AI foundation models for healthcare, with applications spanning anonymization, record linkage, information extraction, summarization and predictive analytics.
Go-to-market
The company emerged from stealth in October 2021 with a public launch, product pages and developer documentation, an API early access program, and a direct sales motion; it hired Chuck Smolky, a former vice president at Optum and Aetna and senior vice president at Health Fidelity, as its first chief commercial officer to lead commercial strategy at the payor-provider interface. Seed proceeds were earmarked for expanding engineering, product and commercial teams and advancing programs with key healthcare systems.
Healthcare providers and provider systems, payors and insurers, digital health companies, pharmaceutical and biotech organizations, diagnostics and laboratory operators, and software engineers and developers building on healthcare data.
Geography
The company announced its launch from Boston and describes serving professionals across the U.S. healthcare system; it states it is remote and hybrid-friendly with offices.
History
ScienceIO was founded in 2019 and spent roughly three years building its data set and platform without public disclosure. It emerged from stealth on October 13, 2021 with $8 million in seed funding, simultaneously appointing its first chief commercial officer and launching an API early access program. In 2022 it was selected as one of four companies in Mayo Clinic Platform_Accelerate, Mayo Clinic's program for making AI startups market-ready. On February 27, 2024, at the ViVE conference, Veradigm announced an agreement to acquire ScienceIO for $140 million.
Risks & controversies
Reporting on the acquisition notes that ScienceIO was entering a market with numerous prior attempts to solve healthcare data structuring, and that the acquirer, Veradigm, faced potential Nasdaq delisting at the time of the deal due to delayed financial reporting stemming from internal control failures, having not filed its 2022 annual report or 2023 quarterly reports.
Compiled by commissioned research from 7 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 5
launches, deals, and filingsVeradigm, the healthcare data and technology company formerly known as Allscripts, announced a $140 million acquisition of ScienceIO to build healthcare large language models. The deal was approved by Veradigm's board, funded through cash on hand, and expected to close promptly; about $44 million of the purchase price is deferred and payable in installments over the first three anniversaries of closing. Veradigm planned to apply the platform to a data set covering 400,000 providers and more than 200 million patients.
$140M source ↗
ScienceIO was chosen as one of four companies for Mayo Clinic's AI startup program, Mayo Clinic Platform_Accelerate, which helps AI-based startups become market-ready.
ScienceIO publicly launched out of stealth mode with $8 million in seed funding from Section 32, Sea Lane Ventures, Quiet Capital, Toba Capital, Dorm Room Fund, Swell Partners, Earl Grey Capital and angel investors including Lachy Groom and Josh Buckley. Proceeds were designated for expanding machine learning repositories and NLP capabilities, advancing programs with healthcare systems, and growing engineering, product and commercial teams.
$8M source ↗
ScienceIO hired Chuck Smolky, previously a vice president at Optum and Aetna and senior vice president at Health Fidelity, as its first chief commercial officer to lead commercial strategy at the payor-provider interface.
Alongside emerging from stealth, ScienceIO launched an early access program giving developers access to its API.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 7
primary sources listed
- ScienceIOscience.io · web
7 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does ScienceIO do?
- ScienceIO builds healthcare AI models that turn unstructured medical text into structured data via API; acquired by Veradigm in 2024.
- Who founded ScienceIO?
- ScienceIO was founded by Will Manidis, Gaurav Kaushik in 2019.
- Who are ScienceIO's investors?
- ScienceIO's investors include Earl Grey Capital, Swell Partners, Toba Capital, Alt Capital, Lachy Groom, Quiet Capital, Section 32, Todd and Rahul’s Angel Fund and 5 more.